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ABSTRACT
Background
Antibodies specifically affect the amygdala in a mouse model of systemic lupus
erythematosus (SLE). The aim of our study was to investigate whether there is also specific
involvement of the amygdala in human SLE.
Methods and Findings
We analyzed a group of 37 patients with neuropsychiatric SLE (NP-SLE), 21 patients with SLE,
and a group of 12 healthy control participants with diffusion weighted imaging (DWI). In
addition, in a subset of eight patients, plasma was available to determine their anti-NMDAR
antibody status. From the structural magnetic resonance imaging data, the amygdala and the
hippocampus were segmented, as well as the white and gray matter, and the apparent
diffusion coefficient (ADC) was retrieved. ADC values between controls, patients with SLE, and
patients with NP-SLE were tested using analysis of variance with post-hoc Bonferroni
correction. No differences were found in the gray or white matter segments. The average ADC
in the amygdala of patients with NP-SLE and SLE (940310
 6 mm
2/s; p¼0.006 and 949310
 6
mm
2/s; p ¼ 0.019, respectively) was lower than in healthy control participants (1152 3 10
 6
mm
2/s). Mann-Whitney analysis revealed that the average ADC in the amygdala of patients
with anti-NMDAR antibodies (n¼4; 802310
 6 mm
2/s) was lower (p¼0.029) than the average
ADC of patients without anti-NMDAR antibodies (n¼4; 979310
 6 mm
2/s) and also lower (p¼
0.001) than in healthy control participants.
Conclusions
This is the first study to our knowledge to observe damage in the amygdala in patients with
SLE. Patients with SLE with anti-NMDAR antibodies had more severe damage in the amygdala
compared to SLE patients without anti-NMDAR antibodies.
The Editors’ Summary of this article follows the references.
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The inﬂuence of the immune system on cognition and
emotion is unclear. Recently, it was shown that antibodies
could alter emotional behavior in a rodent model of human
autoimmune disease, systemic lupus erythematosus (SLE) [1].
SLE is characterized by the production of various types of
autoantibodies; it is the autoimmune disease with the largest
number of detectable autoantibodies [2,3]. The most speciﬁc
autoantibody present in the serum of patients with SLE is
directed against DNA. Neuropsychiatric (NP) symptoms can
occur in SLE patients, and these patients are classiﬁed as
having NP-SLE. These NP symptoms can be divided into
primary, caused by SLE, and secondary to comorbidity in
SLE. The rheumatology department of our institution, which
serves an area of roughly 2 million inhabitants, reported
primary NP-SLE in 30 (15.7%) of 191 patients with SLE, using
data accumulated over a 10-y period [4].
The origin of primary NP symptoms in patients with SLE
has long been a mystery, because the scarce histological
material obtained from such patients failed to provide clues
for interactions between autoantibodies and the brain.
Moreover, it has become clear that different pathogenic
pathways can lead to neurological symptoms in patients with
SLE [5]. Patients with SLE may have autoantibodies, which
interfere with blood clotting, leading to brain infarctions.
SLE patients may also suffer from neurological manifesta-
tions that are presumably caused by antibodies binding to
neural cells [6–8].
Previously, it has been demonstrated that a subset of the
antibodies to double stranded DNA (dsDNA) in patients with
SLE cross-reacts with subunits of the NMDA receptor (anti-
NMDAR antibodies) on neuronal cells and can cause neuro-
nal death by excito-toxicity and apoptosis [7,9]. Under
normal circumstances, the blood-brain barrier (BBB) pre-
vents these antibodies from causing neuronal damage. By
using bacterial lipopolysaccharide to breach the BBB, brain
damage was induced in mice with anti-NMDAR antibodies. In
that model, the hippocampus was preferentially affected [10].
The same mouse model was used to assess whether rises in
epinephrine, a stress hormone which is known to cause leaks
in the BBB, could also induce brain damage in the presence
of anti-NMDAR antibodies. These animals developed a
behavioral disorder characterized by a deﬁcient response to
fear-conditioning paradigms. Symptoms could be explained
by the observed selective neuronal loss in the amygdala, a
structure that is part of the limbic system and is involved in
regulating emotions such as stress, fear, and depression [1].
The aim of our study was to assess whether the hippo-
campus and the amygdala are selectively affected in patients
with NP-SLE and SLE, and whether anti-NMDAR antibodies
are involved in creating changes in these brain structures.
Methods
Patients
We obtained informed consent from all patients and
controls, and the hospital’s commission on scientiﬁc research
on human subjects approved the study protocol.
All patients with SLE fulﬁlled the 1982 American College of
Rheumatology (ACR) revised criteria for SLE [11]. The
patients with SLE had an average SLE disease duration of
4.2 y (SD 4.9). None of the patients with SLE had a history of
or active neurological disease at the time of the scan.
Healthy controls were recruited through advertisement in
a local newspaper. Twelve healthy controls (1 male; 11 female;
mean age 43.8 y; SD 9.5) were included in the study. Healthy
controls were age and sex matched to the general character-
istics of the patient population. Predeﬁned exclusion criteria
for control participants were a history of neurological disease
or pathology on T1- or T2-weighted magnetic resonance
imaging (MRI) scans.
Thirty-seven patients (1 male; 36 female; mean age 36.4 y;
SD 13.0) were diagnosed as having NP-SLE according to the
1999 American College of Rheumatology revised criteria [12].
NP-SLE was diagnosed based on clinical symptoms. The
following neuropsychiatric syndromes were present in our
NP-SLE patient group: Guilian-Barre (n¼1), cerebrovascular
disease (n ¼ 11), headache (n ¼ 12), mononeuropathy (n ¼ 2),
movement disorder (n ¼ 3), myelopathy (n ¼ 3), cranial
neuropathy (n¼1), plexopathy (n¼2), seizures (n¼10), acute
confusional state (n ¼ 2), anxiety disorder (n ¼ 1), cognitive
dysfunction (n ¼9), mood disorder (n ¼5), and psychosis (n ¼
1). There were 20 patients with one syndrome, ten patients
with two syndromes, ﬁve patients with three syndromes, and
two patients with four syndromes. Special care was taken to
exclude any other possible causes of NP symptoms, so that
only patients with primary NP-SLE were included in the
group [12]. There was no indication of other previous
neurological or psychiatric disease in any of the participants.
The patients with NP-SLE had an average SLE disease
duration of 9.4 y (SD 8.8) and a history of neuropsychiatric
involvement for an average of 4.5 y (SD 5.3). At the time of the
scan, 11 patients had active disease deﬁned as having had
symptoms up to 6 mo before the scan. The remaining 26
patients had inactive disease, deﬁned as having had no
symptoms for at least 6 mo.
In addition, plasma was available to determine the anti-
NMDAR antibody status in a subset of eight patients [7]
(courtesy of Betty Diamond, Department of Medicine,
Columbia University Medical Center, New York, United
States). Autoantibodies to a linear epitope of the NR2
subunit of the NMDA receptor were assessed in eight patients
by enzyme-linked immunosorbent assay (ELISA) using 96-well
microtiter plates. In each assay, ﬁve negative control sera
were included. The plates were read after 90 min and optical
density (OD) was monitored at 405 nm. The anti-peptide
antibody ELISA was performed as described previously by
Putterman and Diamond [13]. Patients were considered to be
anti-NMDAR antibody–positive based on the cut-off value of
2 standard deviations above the mean OD of the control sera.
Mean OD values (6SD) in NMDA-positive patients were
0.469 (60.103, range 0.382–0.609) and 0.329 (60.108, range
0.173–0.405).
In the group of anti-NMDAR antibody–positive patients,
only one patient was anti-dsDNA antibody–positive (anti-
dsDNA titers were measured at the time of the diffusion
weighted imaging [DWI] scan). All anti-NMDAR antibody–
negative patients were anti-dsDNA antibody–negative. This
ﬁnding is in line with the previous study of Husebye showing
no association between the anti-dsDNA antibodies and anti-
NMDAR antibodies [14].
The patients with NP-SLE received one or more of the
following medications for their NP symptoms at the time of
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Involvement of the Amygdala in SLEscan: methylprednisolone (n ¼ 11), cyclophosphamide (n ¼ 6),
azothioprane (Imuran) (n ¼ 10), prednisone (n ¼ 12),
carbasalate calcium (Ascal) (n ¼ 8), and fenprocoumon
(Marcoumar) (n ¼ 7). One patient underwent plasmapheresis
and received intravenous immunoglobulin therapy. Eight
patients were without any medication for their NP symptoms
at the time of the scan. The majority of the patients with SLE
had been treated with corticosteroids prior to the MRI scan.
However, as recently demonstrated, DWI parameters are not
inﬂuenced by oral corticosteroids [15].
Imaging
All patients underwent DWI, an MRI technique that is
particularly sensitive to structural brain damage, in which the
apparent diffusion coefﬁcient (ADC) is a measure reﬂecting
tissue integrity in a quantitative way. Scan-rescan reprodu-
cibility of the mean ADC values has previously been shown to
be robust [16]. The DWI consisted of a multishot spin-echo
echo planar imaging (EPI) sequence, with an EPI factor
deﬁned as the number of rows in K-space collected per
excitation, of 15. The total echo time was 114 ms. Other
parameters were as follows: 256 3 128 matrix, 20 axial
sections of 6 mm with an intersection gap of 1 mm, and a ﬁeld
of view of 230 mm covering the whole brain. The b factor was
800 s/mm
2 applied to measure diffusion in three orthogonal
directions. The maximum gradient strength of the machine
was 23 mT/m. The slew rate of the system was 105 T/m/sec
with a rise time of 0.22 s. From the DWI images in each of the
three orthogonal directions, an average DWI was calculated.
The ADC maps of the whole brain were calculated from the
average DWI and b0 images on a voxel-by-voxel basis.
Post-processing
We automatically segmented the cortical gray matter and
white matter using Software for Neuro-Image Processing in
Experimental Research (SNIPER), an in-house–developed
program for image processing (Figure 1) [17]. In addition,
we manually segmented regions of interest (ROIs) on
coregistered T1 weighted images in the amygdala and in the
hippocampus (Figure 2), on which the clinical status of the
patient had been hidden. These ROIs subsequently mapped
on the ADC maps. The average ADC was calculated for the
ROIs, the white matter, and the gray matter. Macroscopic
lesions were not included in the ROI.
Statistical Analysis
Average ADC values from white and gray matter as well as
from the ROIs were compared between controls and patients
with NP-SLE using ANOVA analysis with post-hoc Bonferroni
correction. An exact p value lower than 0.05 was considered
signiﬁcant. To test for differences between the controls and
the anti-NMDAR– positive and –negative patients, non-
parametric Mann-Whitney tests were used to account for
differences in group size as well as small sample size.
Results
The ADC values of gray matter, white matter, hippo-
campus, and amygdala in controls, patients with NP-SLE, and
patients with SLE are shown in Table 1. No difference in the
gray matter, white matter, or the hippocampus was found
between groups. In patients with SLE (p ¼ 0.019) as well as in
patients with NP-SLE (p ¼ 0.006), the ADC was decreased in
the amygdala compared to controls. There was no difference
in ADC values of the amygdala between patients with SLE and
those with NP-SLE.
Figure 1. Axial Calculated Magentization Transfer Ratio Image Showing
Segmentation of Cebrebrospinal Fluid (Dark Blue), the Gray Matter
(Turquoise), and the White Matter (Brown)
doi:10.1371/journal.pmed.0030499.g001
Figure 2. Axial T1 Weighted Anatomical MRI Scan Showing Segmenta-
tion of the Amygdala (Yellow) and the Hippocampus (Red)
doi:10.1371/journal.pmed.0030499.g002
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Involvement of the Amygdala in SLETable 2 shows ADC values of the hippocampus and the
amygdala in control participants, anti-NMDAR–negative NP-
SLE patients, and anti-NMDAR–positive NP-SLE patients. In
patients with anti-NMDAR antibodies, the ADC was de-
creased (p¼0.001) compared to the healthy controls, whereas
this was not the case (p ¼ 0.262) for the patients without the
anti-NMDAR antibodies. In addition, the ADC in anti-
NMDAR–positive patients is decreased (p ¼ 0.029) compared
to patients without these antibodies.
Discussion
This is the ﬁrst study to our knowledge to observe selective
damage in the amygdala in patients with SLE. In contrast, we
did not ﬁnd signiﬁcant changes in ADC of the white matter,
gray matter, or the hippocampus. These ﬁndings indicate that
the amygdala is speciﬁcally affected by the autoantibodies
and also suggests that the animal model in which the BBB is
opened by increased cerebral blood ﬂow induced by a stress
hormone could be an appropriate reﬂection of human
disease. Although the sample size is small, we observed more
severe changes in patients with SLE with anti-NMDAR
antibodies as compared to patients with SLE without anti-
NMDAR antibodies, suggesting that these antibodies induce
brain damage. The low ADC in the amygdala is compatible
with the presence of cytotoxic edema [18].
The ﬁnding that the amygdala in patients with SLE is
signiﬁcantly different from that in healthy controls is in line
with the report in the mouse model of SLE, showing that
antibodies can affect the limbic system, which can result in
altered emotions [1]. Usually, animal models of human
diseases are only an approximation of actual disease in
humans. However, the ﬁnding that the amygdala is selectively
involved and that this involvement was more pronounced in
patients with anti-NMDAR antibodies than in patients with-
out these antibodies supports the validity of this mouse
model.
Epinephrine is released under circumstances of stress, and
patients with SLE often relate the occurrence of major stress
to the induction of organ involvement. Although epidemio-
logical data are currently lacking for a correlation between
episodes of stress and the development of NP symptoms in
SLE patients, such a relation could explain our data.
Furthermore, in the mouse model, the stress hormone
epinephrine opened the BBB at the site of the amygdala.
This observation would also explain the selective involvement
of the amygdala compared to the residual brain tissue in our
patients.
A limitation of our study is the small number of
participants. Given the different pathogenetic pathways
leading to NP symptoms in patients with SLE, such as those
secondary to lupus nephritis or mediated by anti-phospho-
Table 1. Mean ADC Values (310
 6 mm
2/s) and Standard Deviations for all Participants
Region of
Interest
Controls
[Mean
(SD)]
NP-SLE
[Mean
(SD)]
SLE
[Mean
(SD)]
Controls
versus SLE
(Mean
Difference)
95%
Confidence
Interval
Controls
versus NP-
SLE (Mean
Difference)
95%
Confidence
Interval
SLE versus
NP-SLE
(Mean
Difference)
95%
Confidence
Interval
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
Gray matter 1,004.9 (59.5) 1,033.0 (122.9) 982.2 (70.4) 22.6  67.0 112.2  28.1  110.4 54.1  50.8  118.4 16.9
White matter 838.6 (31.5) 879.1 (123.8) 832.8 (51.4) 5.8  79.4 91.0  40.4  118.6 37.8  46.2  110.5 18.1
Hippocampus 1,125.0 (322.5) 1,096.6 (297.1) 1208.9 (323.2)  83.9  358.7 191.0 28.4  223.9 280.7 9.5  95.2 319.8
Amygdala 1,151.6 (258.3) 939.6 (185.1) 949.2 (182.7) 202.4 26.2 378.7 212.0 50.2 373.7 112.3  123.5 142.6
Mean differences and confidence intervals calculated by ANOVA analysis with post-hoc Bonferroni correction
doi:10.1371/journal.pmed.0030499.t001
Table 2. Mean ADC Values (310
 6 mm
2/s) and Standard Deviations for Controls, Anti-NMDAR–Positive and –Negative Participants
Region of
Interest
Controls
[Mean
(SD)]
Anti-
NMDAR–
Negative
[Mean
(SD)]
Anti-
NMDAR–
Positive
[Mean
(SD)]
Controls
versus
Anti-NMDAR–
Negative
(Mean
Difference)
95%
Confidence
Interval
Controls
versus
Anti-NMDAR–
Positive
(Mean
Difference)
95%
Confidence
Interval
Anti-NMDAR–
Negative versus
Anti-NMDAR–
Positive
(Mean
Difference)
95%
Confidence
Interval
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
Lower
Bound
Upper
Bound
Amygdala 1,151.6 (258.3) 979.0 (126.9) 802.0 (31.2) 172.6  156.8 502.0 349.6 20.2 679.0 177.0  226.4 580.4
Hippocampus 1,125.0 (322.5) 1081.7 (141.1) 936.6 (77.6) 43.3  367.7 454.2 188.5  222.5 599.4 145.2  358.1 648.5
Mean differences and confidence intervals calculated by ANOVA analysis with post-hoc Bonferroni correction
doi:10.1371/journal.pmed.0030499.t002
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Involvement of the Amygdala in SLElipid antibodies, we took great care in patient selection that
only patients in whom extensive work-up revealed that the
symptoms were most likely to be caused by primary SLE or
NP-SLE were included. As mentioned earlier, the number of
new patients with primary SLE or NP-SLE referred to a
tertiary referral center such as ours over a long period of time
is not substantial [4]. Hence, there are not a large number
patients available to study. Further, the number of patients
eligible for anti-NMDAR determination is also limited.
However, the effects measured in the amygdala are consistent
and in contrast with the trends for increased ADC values
found in the remaining brain tissue. Still, we recognize that
for the clinical validation of our ﬁndings, a much larger
sample will be required. Another limitation of our study
could be the relatively small ROI drawn in the hippocampus;
this limitation occurs because of the axial orientation of the
scan slices, which is not the ideal orientation for hippocampal
segmentation. Nonetheless, this limitation has no inﬂuence
on the ﬁndings in the amygdala, although further studies
using coronal slices for more extensive hippocampal seg-
mentation could possibly reveal effects in the hippocampus as
well.
Our observations provide an insight into the interplay of
the immune system on the one hand and cognition and
emotion on the other. The immune system, through the
generation of autoantibodies that cross-react with neuronal
receptors, can cause damage of speciﬁc brain structures
resulting in speciﬁc types of cognitive and/or emotional
changes. Alternatively, emotions may render speciﬁc brain
structures more vulnerable through increased secretion of
stress hormones that breach the BBB in speciﬁc brain areas.
This is, to our knowledge, the ﬁrst example of the elucidation
of a pathogenetic mechanism by which major stress could
lead to an organic brain syndrome.
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Involvement of the Amygdala in SLEEditors’ Summary
Background. The human body is continually attacked by viruses,
bacteria, fungi, and parasites, but the immune system usually prevents
these pathogens from causing disease. To be effective, the immune
system has to respond rapidly to foreign antigens (bits of proteins that
are unique to the pathogen) but ignore self-antigens. In autoimmune
diseases, this ability to discriminate between self and nonself fails for
unknown reasons, and the immune system begins to destroy human
tissues. In the chronic autoimmune disease systemic lupus erythemato-
sus (SLE or lupus), the immune system attacks the skin, joints, nervous
system, and many other organs. Patients with SLE make numerous
‘‘autoantibodies’’ (antibodies are molecules made by the immune
system that recognize and attack antigens; autoantibodies attack self-
antigens). These autoantibodies start the attack on the body; then other
parts of the immune system join in, causing inflammation and forming
deposits of immune cells, both of which damage tissues. Common
symptoms of SLE include skin rashes and arthritis, but some patients
develop NP-SLE, a form of SLE that includes neuropsychiatric symptoms
such as amnesia, dementia, mood disorders, strokes, and seizures. There
is no cure for SLE, but mild cases are controlled with ibuprofen and other
non-steroidal anti-inflammatory drugs; severe cases are kept in check
with corticosteroids and other powerful immunosuppressants.
Why Was This Study Done? In most of the tissues affected by SLE, the
damage done by autoantibodies and immune cells can be seen when
the tissues are examined with a microscope. But there is little
microscopic damage visible in the brains of patients with NP-SLE. More
generally, it is unclear how or even whether the immune system affects
mental functions and emotion. In this study, researchers used magnetic
resonance imaging (MRI) to investigate whether there are any structural
changes in the brains of patients with NP-SLE that could explain their
neuropsychiatric symptoms. They have also examined whether any
changes in the brain can be linked to the presence of autoantibodies
that recognize a protein called the NMDA receptor (anti-NMDAR
antibodies) that is present on brain cells.
What Did the Researchers Do and Find? The researchers used an MRI
technique called diffusion weighted imaging to examine the brains of
several patients with NP-SLE or SLE and the brains of several healthy
individuals. Using this technique, it is possible to quantify the amount of
structural damage in different regions of the brain. The researchers
found no differences in most areas of the brain between the two groups
of patients and the healthy controls. However, there were clear signs of
damage in the amygdala (the part of the brain that regulates emotions
and triggers responses to danger) in the patients with SLE or NP-SLE
when compared to the control individuals. The researchers also found
that the damage was more severe in the patients who had anti-NMDAR
autoantibodies than in those that did not have these autoantibodies.
What Do These Findings Mean? These findings suggest that autoanti-
bodies produced by patients with SLE specifically damage the amygdala,
a discovery that helps to explain some of the neuropsychiatric symptoms
of this condition. Previous work has shown that the treatment of mice
with anti-NMDAR antibodies and epinephrine, a stress hormone that
causes leaks in the blood-brain barrier (antibodies can’t usually get into
the brain because of this barrier), results in damage to the amygdala and
a deficient response to dangerous stimuli. The researchers suggest that a
similar series of events might happen in SLE—patients often mention
that a period of major stress precedes the development of symptoms. To
provide stronger evidence for such a scenario, a detailed study of how
stress relates to neuropsychiatric symptoms is needed. The damage to
the amygdala (and the lack of damage elsewhere in the brain) and the
possible association between brain damage and anti-NMDAR antibodies
seen in this small study also need to be confirmed in more patients.
Nevertheless, these findings provide an intriguing glimpse into the
interplay between the immune system and the brain and into how stress
might lead to physical damage in the brain.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030499.
  MedlinePlus encyclopedia pages on autoimmunity and on systemic
lupus erythematosus
  US National Institute of Arthritis and Musculoskeletal and Skin Diseases
booklet for patients with SLE
  American College of Rheumatology information for patients on SLE
  NHS Direct Online Health Encyclopedia pages on SLE
  The Lupus Foundation of America information and support for
patients with SLE
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